Taizhou, March 27, 2024/PRNewswire/ -- Recently, Jiangsu Ruike Biotechnology Co., Ltd. (hereinafter referred to as “Recobiology”, stock code: 02179.HK) and Shanghai Rongsheng Biopharmaceutical Co., Ltd. (hereinafter referred to as “Rongsheng Biotech”) successfully held a novel adjuvant vaccine R&D project signing and project launch meeting in Shanghai. At the meeting, the two sides signed a strategic cooperation agreement on the novel adjuvant vaccine project and discussed in depth the details of the project progress.
Adjuvants are important components in vaccine development, and novel adjuvants have become the key to the success of innovative vaccine development. According to the terms of the agreement, the two sides will jointly develop a novel adjuvant vaccine. Recobiology will provide novel adjuvants independently developed based on the novel adjuvant technology platform, and Rongsheng Biotech will provide independently designed viral antigens. The project will improve immunogenicity and achieve the goal of optimizing immunization procedures by empowering the existing Rongsheng Biotech vaccine with novel adjuvants.
Dr. Liu Yong, founder, chairman of the board of directors and general manager of Recobiology, said, “This cooperation is an important milestone in empowering partners in the industry chain of Ricoh Biosciences. Novel adjuvants play a critical role in the development and application of innovative vaccines. Relying on its self-developed novel adjuvant technology platform, Recobiology has successfully developed a variety of innovative vaccines with excellent clinical performance, great competitiveness and market potential. We look forward to the early fruition of our strategic cooperation with Rongsheng Biotech, and we also believe that the cooperation between the two sides will further promote the innovation and development of human vaccines.”
Zhu Shaorong, founder and chairman of Rongsheng Biotech, said, “Rongsheng Biotech has built a key core technology platform for the 'virus+bacteria' vaccine based on independent innovation and research. It has large-scale production capacity, and has achieved breakthroughs in technological innovation and upgrading in scientific research on various vaccine products under development. This strategic cooperation targets cutting-edge vaccine innovation and market demand, makes full use of the scientific research advantages and innovative achievements of the two sides, and continues to cooperate deeply to jointly advance the development and commercialization process of novel adjuvant vaccines. We are confident that we and Recobiotics will work together to achieve strategic cooperation results to benefit human life, health and public health safety with better clinical performance.”
About Rongsheng Biotech
Shanghai Rongsheng Biopharmaceutical Co., Ltd. (hereinafter referred to as “Rongsheng Biology” or the “Company”) was founded in 1988. It is a national high-tech enterprise engaged in R&D, production and sales of vaccines and in vitro diagnostic reagents, and a “little giant” enterprise specializing in the development, production and sale of vaccines and in vitro diagnostic reagents. The company always keeps in mind “being in charge of the biomedical industry for human health!” The mission is to actively participate in research on major national science and technology projects and participate in the formulation of 5 industry standards. Over the past 36 years, the company has continuously optimized and improved its scientific research strength and industrialization capabilities through independent innovation and research. Based on advanced production processes and stricter product registration standards compared to the Pharmacopeia, the company's third-generation “Vikobon” live attenuated chickenpox vaccine has received market recognition by not adding gelatin or human blood albumin to the product. Since its launch, it has served 31 provinces, autonomous regions and municipalities across the country; the company has built a multi-level and rich R&D pipeline and innovative and upgraded product matrices. The company will further develop its comprehensive competitive advantages in product R&D and innovation, large-scale production, sales channels and quality management, promote the high-quality development of the company's comprehensive technological innovation and industrialization capabilities, serve the national life and health strategy, and serve people's public health and safety.
About Ricoh Biotech
Jiangsu Ruike Biotechnology Co., Ltd. (hereinafter referred to as “Recobiotics” or the “Company”, Hong Kong Stock Exchange stock code: 02179) was founded in 2012 and is an innovative vaccine company with independent research and development technology as the core driving force. The company has always adhered to the mission of “creating first-class vaccines and protecting human health”. By strategically focusing on the burden of major infectious diseases, the company has built a major vaccine product pipeline portfolio with independent intellectual property rights to meet public health needs that are far from being met. After more than 20 years of technical accumulation, Recobiotics has built three innovative platforms for novel adjuvants, protein engineering, and immune evaluation. The company is one of the few companies in the world capable of developing and producing a full range of novel adjuvants. The company's three platforms work closely together to continuously develop major vaccine varieties with leading performance. Driven by a strong innovation platform, the company has built a high-value innovative vaccine pipeline portfolio with more than 10 major varieties, covering major diseases such as cervical cancer, shingles, COVID-19, respiratory syncytial virus, cytomegalovirus, and herpes simplex virus infections, leading the country in product development and clinical progress. After ten years of sharpening the sword and accumulating sparse resources, Recobiotics is about to enter a period of explosion in product commercialization.
Forward-looking statement
This press release may include forecasts, estimates, forecasts, objectives, opinions, prospects, results, returns, and forward-looking statements relating to the Group's financial position, operating performance, capital position, strategy and business, which may be determined by using forward-looking terms such as “may,” “will,” “should,” “anticipate,” “anticipate,” “project,” “plan,” “estimate,” “seek”, “plan,” “aim,” “believe,” “potential,” and “reasonably likely” or “reasonably likely” or denial of variation Text or similar terms (collectively, “forward-looking statements”), including strategic priorities, research and development projects and any financial, investment, and capital goals and any other goals, commitments, and ambitions described in this presentation in writing or orally. Any such forward-looking statements are not a reliable indicator of future results, as they may involve important statements or implied assumptions and subjective judgments that may or may not be proven to be correct, accurate, or complete. There is no guarantee that any of the matters set out in the forward-looking statements will be achievable, will actually occur or will be realized, or complete or accurate. These assumptions and judgments may prove incorrect, inaccurate or incomplete, and involve known and unknown risks, uncertainties, contingencies and other significant factors, many of which are beyond the control of the Group. There is also no guarantee that the Group can successfully develop or sell its core products or other candidate products. Due to various risks, uncertainties, and other factors (including but not limited to general market conditions, regulatory changes, geopolitical tensions, or data limitations and changes). Any such forward-looking statement is based on the Group's beliefs, expectations and opinions as of the date the statement was made. If circumstances or management's beliefs, expectations, or opinions change, the Group does not assume and hereby disclaims any responsibility or obligation to update, modify, or supplement these statements. For these reasons, you should not rely on any forward-looking statements and be clearly cautioned that you should not rely on any forward-looking statements. The Group or its representatives make no express or implied representation or warranty as to the fulfillment or fairness of any of the predictions, estimates, projections, objectives, promises, prospects, or rewards contained in this presentation.
Investor Inquiries:
Email: ir@recbio.cn
Tel: +86-0523-86818860
Media inquiries:
Email: media@recbio.cn
Tel: +86-0523-86818860